Colistin loading dose: evaluation of the published pharmacokinetic and clinical data.

[1]  D. Schlossberg,et al.  COLY-MYCIN® M PARENTERAL (Colistimethate for Injection) , 2017 .

[2]  K. Porter,et al.  Efficacy and Safety of a Colistin Loading Dose, High-Dose Maintenance Regimen in Critically Ill Patients With Multidrug-Resistant Gram-Negative Pneumonia , 2017, Journal of intensive care medicine.

[3]  A. Trifi,et al.  Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series , 2016, Chemotherapy.

[4]  A. Levin,et al.  Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B , 2016, Antimicrobial Agents and Chemotherapy.

[5]  K. Fountas,et al.  Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin , 2016, Acta Neurochirurgica.

[6]  V. Rai,et al.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis , 2016, Intensive Care Medicine.

[7]  F. Puntillo,et al.  Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Turnidge,et al.  New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. , 2015, The Journal of antimicrobial chemotherapy.

[9]  R. Bellomo,et al.  A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. , 2015, American journal of respiratory and critical care medicine.

[10]  S. Bauer,et al.  Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli , 2015, Antimicrobial Agents and Chemotherapy.

[11]  M. Bassetti,et al.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study--authors' response. , 2015, The Journal of antimicrobial chemotherapy.

[12]  Ronald N. Jones,et al.  Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination , 2015, Antimicrobial Agents and Chemotherapy.

[13]  A. Koutsoukou,et al.  Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients , 2015, Antimicrobial Agents and Chemotherapy.

[14]  M. Falagas,et al.  Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit , 2015, Infectious diseases.

[15]  M. Bassetti,et al.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. , 2015, The Journal of antimicrobial chemotherapy.

[16]  N. Thuy,et al.  The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: Use of colistin in a population of lower body weight. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[17]  A. Valachis,et al.  The Role of Aerosolized Colistin in the Treatment of Ventilator-Associated Pneumonia: A Systematic Review and Metaanalysis* , 2015, Critical care medicine.

[18]  C. Landersdorfer,et al.  Colistin: How should It Be Dosed for the Critically Ill? , 2015, Seminars in Respiratory and Critical Care Medicine.

[19]  Brian T. Tsuji,et al.  Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. , 2015, The Lancet. Infectious diseases.

[20]  K. Kaye,et al.  Colistin: Understanding and Applying Recent Pharmacokinetic Advances , 2015, Pharmacotherapy.

[21]  L. Danziger,et al.  To B or Not to B, That Is the Question: Is It Time to Replace Colistin With Polymyxin B? , 2015, Pharmacotherapy.

[22]  W. Couet,et al.  New Colistin Population Pharmacokinetic Data in Critically Ill Patients Suggesting an Alternative Loading Dose Rationale , 2014, Antimicrobial Agents and Chemotherapy.

[23]  Matthieu Jacobs,et al.  Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients , 2014, Antimicrobial Agents and Chemotherapy.

[24]  M. Falagas,et al.  Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections , 2014, Emerging infectious diseases.

[25]  U. Theuretzbacher.  Product information for parenteral colistin varies substantially across Europe. , 2014, The Journal of antimicrobial chemotherapy.

[26]  M. Falagas,et al.  Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[27]  O. Cars,et al.  A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. , 2014, The Journal of antimicrobial chemotherapy.

[28]  V. Tam,et al.  In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy , 2014, Antimicrobial Agents and Chemotherapy.

[29]  J. Li,et al.  Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration , 2014, Antimicrobial Agents and Chemotherapy.

[30]  V. Miriagou,et al.  Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems , 2014, Antimicrobial Agents and Chemotherapy.

[31]  Brian T. Tsuji,et al.  Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. , 2013, The Journal of antimicrobial chemotherapy.

[32]  S. Luque,et al.  Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study , 2013, BMC Infectious Diseases.

[33]  L. Leibovici,et al.  Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems , 2013, Antimicrobial Agents and Chemotherapy.

[34]  M. Falagas,et al.  Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis , 2013, Expert review of anti-infective therapy.

[35]  M. Falagas,et al.  Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? , 2013, The Journal of infection.

[36]  N. Gogtay,et al.  Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection , 2013, European Journal of Clinical Pharmacology.

[37]  N. Petrosillo,et al.  Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art , 2013, Expert review of anti-infective therapy.

[38]  S. Bauer,et al.  Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  R. Bellomo,et al.  Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  M. Falagas,et al.  Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  E. Alp,et al.  Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[42]  Lena E. Friberg,et al.  Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill , 2012, Antimicrobial Agents and Chemotherapy.

[43]  F. Puntillo,et al.  High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  G. Drusano,et al.  Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target , 2012, Antimicrobial Agents and Chemotherapy.

[45]  T. Hirama,et al.  Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects , 2011, Current medical research and opinion.

[46]  J. Li,et al.  Dosing of colistin-back to basic PK/PD. , 2011, Current opinion in pharmacology.

[47]  W. Couet,et al.  Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80‐mg Intravenous Dose of CMS in Young Healthy Volunteers , 2011, Clinical pharmacology and therapeutics.

[48]  A Forrest,et al.  Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.

[49]  T. Tsaganos,et al.  Impact of Multidrug Resistance on Experimental Empyema by Pseudomonas aeruginosa , 2011, Respiration.

[50]  D. Sofianou,et al.  Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. , 2011, The Journal of antimicrobial chemotherapy.

[51]  Cathrine A. McKenzie.  Antibiotic dosing in critical illness. , 2011, The Journal of antimicrobial chemotherapy.

[52]  G. Iotti,et al.  Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. , 2010, Chest.

[53]  J. Turnidge,et al.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. , 2010, The Journal of antimicrobial chemotherapy.

[54]  P. Singer,et al.  Effectiveness and safety of colistin: prospective comparative cohort study. , 2010, The Journal of antimicrobial chemotherapy.

[55]  J. Li,et al.  Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. , 2010, The journal of physical chemistry. B.

[56]  M. Falagas,et al.  Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. , 2010, International journal of antimicrobial agents.

[57]  J. Turnidge,et al.  Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models , 2009, Antimicrobial Agents and Chemotherapy.

[58]  M. Falagas,et al.  Nephrotoxicity of colistin: new insight into an old antibiotic. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  A. Armaganidis,et al.  Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria , 2009, Antimicrobial Agents and Chemotherapy.

[60]  T. Tsaganos,et al.  The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study. , 2008, International journal of antimicrobial agents.

[61]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[62]  M. Falagas,et al.  Attributable mortality of Acinetobacter baumannii: no longer a controversial issue , 2007, Critical care.

[63]  J. Li,et al.  Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii , 2006, Antimicrobial Agents and Chemotherapy.

[64]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[65]  M. Falagas,et al.  Toxicity of polymyxins: a systematic review of the evidence from old and recent studies , 2006, Critical care.

[66]  M. Falagas,et al.  Nephrotoxicity of intravenous colistin: a prospective evaluation. , 2005, International journal of antimicrobial agents.

[67]  Matthew E Falagas,et al.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  M. Falagas,et al.  Toxicity after prolonged (more than four weeks) administration of intravenous colistin , 2005, BMC infectious diseases.

[69]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[70]  J. Turnidge,et al.  Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration , 2003, Antimicrobial Agents and Chemotherapy.

[71]  A. Van Schepdael,et al.  Liquid chromatography-ion trap tandem mass spectrometry for the characterization of polypeptide antibiotics of the colistin series in commercial samples. , 2002, Journal of chromatography. A.

[72]  J. Turnidge,et al.  Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High-Performance Liquid Chromatography , 2002, Antimicrobial Agents and Chemotherapy.

[73]  E. Roets,et al.  Isolation and structural characterization of colistin components. , 2001, The Journal of antibiotics.

[74]  A. Bhargava,et al.  Survival or Safety: Balancing act with Colistin , 2015, Journal of global infectious diseases.

[75]  P. Colombo,et al.  Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics. , 2014, International journal of antimicrobial agents.

[76]  You-ning Liu,et al.  eview n vitro synergy of polymyxins with other antibiotics for Acinetobacter aumannii : A systematic review and meta-analysis , 2014 .

[77]  L. Leibovici,et al.  Colistin: new lessons on an old antibiotic. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[78]  P. Rafailidis,et al.  Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. , 2008, Clinical therapeutics.

[79]  M. Falagas,et al.  Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. , 2007, International journal of antimicrobial agents.

[80]  J. Barrett,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). , 1997, Expert opinion on investigational drugs.